- Home
- ZVSA vs CISS Comparison
ZVSA vs CISS Comparison
Compare ZVSA & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- CISS
- Stock Information
- Founded
- ZVSA 2014
- CISS 2022
- Country
- ZVSA United States
- CISS Greece
- Employees
- ZVSA N/A
- CISS N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- CISS Marine Transportation
- Sector
- ZVSA Health Care
- CISS Consumer Discretionary
- Exchange
- ZVSA Nasdaq
- CISS Nasdaq
- Market Cap
- ZVSA 3.0M
- CISS 2.8M
- IPO Year
- ZVSA N/A
- CISS N/A
- Fundamental
- Price
- ZVSA $0.65
- CISS $3.29
- Analyst Decision
- ZVSA
- CISS
- Analyst Count
- ZVSA 0
- CISS 0
- Target Price
- ZVSA N/A
- CISS N/A
- AVG Volume (30 Days)
- ZVSA 1.4M
- CISS 121.0K
- Earning Date
- ZVSA 08-08-2025
- CISS 08-21-2025
- Dividend Yield
- ZVSA N/A
- CISS N/A
- EPS Growth
- ZVSA N/A
- CISS N/A
- EPS
- ZVSA N/A
- CISS N/A
- Revenue
- ZVSA N/A
- CISS $38,174,754.00
- Revenue This Year
- ZVSA N/A
- CISS N/A
- Revenue Next Year
- ZVSA N/A
- CISS N/A
- P/E Ratio
- ZVSA N/A
- CISS N/A
- Revenue Growth
- ZVSA N/A
- CISS N/A
- 52 Week Low
- ZVSA $0.47
- CISS $2.85
- 52 Week High
- ZVSA $6.30
- CISS $23.25
- Technical
- Relative Strength Index (RSI)
- ZVSA 50.60
- CISS 41.39
- Support Level
- ZVSA $0.65
- CISS $3.06
- Resistance Level
- ZVSA $0.73
- CISS $3.36
- Average True Range (ATR)
- ZVSA 0.06
- CISS 0.38
- MACD
- ZVSA 0.00
- CISS -0.04
- Stochastic Oscillator
- ZVSA 36.04
- CISS 16.42
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.